RxDoctor Payments DataLook up a doctor →

Scott Woodfield

Interventional Cardiology · Charleston, SCNPI 1568455723

Payments from drug & device makers

$29,269in general payments, 2019–2025

Across 916 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$8K
  • Edwards Lifesciences$3K
  • Boston Scientific$1K
  • Medtronic$1K
  • Cardiovascular Systems Inc.$1K
  • Amgen$1K
  • plus $13K from 52 others

What the payments were for

  • Travel & lodging$1,5967%
  • Food & beverage$20,66093%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.60$7,984
Edwards Lifesciences75$3,396
Boston Scientific42$1,448
Medtronic(2 entities)30$1,260
Cardiovascular Systems Inc.18$1,243
Amgen89$1,173
Johnson & Johnson89$1,159
Boehringer Ingelheim60$1,018
Abbott27$891
AstraZeneca57$843
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)37$762
Novartis39$633
Inari Medical, Inc.3$598
Pfizer35$575
Alnylam Pharmaceuticals Inc.26$463
Shockwave Medical, Inc18$458
Atricure, Inc.15$427
CMS Imaging, Inc.2$411
Heartflow, Inc.10$346
Biotronik Inc.20$327
Philips North America LLC8$301
Esperion Therapeutics, Inc.12$294
Actelion Pharmaceuticals US, Inc.25$275
Sanofi-aventis U.S. LLC15$250
Bridgebio Pharma, Inc.5$235
Siemens Medical Solutions USA, Inc.2$229
Scpharmaceuticals Inc.11$214
Livanova USA, Inc.1$192
Stryker4$191
Abiomed2$165
Kiniksa Pharmaceuticals, Ltd.8$150
Regeneron Healthcare Solutions, Inc.9$142
Kiniksa Pharmaceuticals International, PLC6$135
Amarin Pharma, Inc.8$127
Merck8$121
United Therapeutics Corporation5$82
Bard Peripheral Vascular, Inc.1$76
Novo Nordisk3$74
Astellas Pharma US Inc4$67
Akcea Therapeutics, Inc.3$64
Cardinal Health 200 LLC3$55
Cardiva Medical, Inc.2$52
Irhythm Technologies, Inc.1$42
Vital Connect, Inc1$40
Terumo Medical Corporation2$38
Bayer2$35
Impulse Dynamics (USA) Inc.2$29
Angiodynamics, Inc.1$26
Daiichi Sankyo Inc.1$21
Teleflex LLC1$21
Lundbeck LLC1$18
Lexicon Pharmaceuticals, Inc.1$17
Cvrx, Inc.1$16
Reflow Medical Inc1$16
Aegerion Pharmaceuticals, Inc.1$15
Cashflow Solutions, LLC1$10
Bardy Diagnostics, Inc.1$10
Thrombolex, Inc.1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,269 in reported general payments places this provider in the 70th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$403,189
Medicare patients
1,350
Services billed
4,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$341,213
XareltoRivaroxaban128$141,821
EntrestoSacubitril/Valsartan104$120,733
Repatha SureclickEvolocumab100$85,205
JardianceEmpagliflozin37$36,952
MultaqDronedarone Hcl19$29,908
Praluent PenAlirocumab40$21,865
Droxidopa11$13,851
FarxigaDapagliflozin Propanediol11$7,710
Diltiazem 24hr Er (Cd)Diltiazem Hcl206$6,668
NexlizetBempedoic Acid/Ezetimibe11$5,751
Metoprolol Succinate401$5,691
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,792
Ezetimibe119$3,718
Atorvastatin Calcium266$3,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$575$341,213305 claims
Johnson & JohnsonXarelto$1,159$141,821128 claims
NovartisEntresto$633$120,733104 claims
Boehringer IngelheimJardiance$1,018$36,95237 claims
Sanofi-aventis U.S. LLCMultaq$250$29,90819 claims
AstraZenecaFarxiga$843$7,71011 claims
Esperion Therapeutics, Inc.Nexlizet$294$5,75111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →